Splenic irradiation in myelofibrosis with myeloid metaplasia: A review

Blood Reviews

Volumn 13, Issue 3, 1999, Pages 163-170

  Elliott, M A ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN;

ABDOMINAL DISCOMFORT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANDROGEN THERAPY; BONE MARROW SUPPRESSION; ERYTHROCYTE TRANSFUSION; HUMAN; HYPERMETABOLISM; LEUKOCYTOSIS; MYELOFIBROSIS; MYELOID METAPLASIA; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SPLEEN; SPLENECTOMY; SPLENOMEGALY; SURVIVAL; THROMBOCYTOSIS;

EID: 0032821818     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.1999.0110     Document Type: Review

References (36)

1. Dameshek W. Some speculations on the myeloproliferative syndromes (editorial). Blood. 6:1951;372-375.
2. Reilly J. T. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev. 11:1997;233-242.
3. Gilbert H. S. The spectrum of myeloproliferative disorders. Med Clin North Am. 57:1973;355-393.
4. Rosenthal D. S. Myeloid metaplasia with myelofibrosis (agnogenic and postpolycythemia vera). Wasserman L. R., Berk P. D., Berlin N. I. Polycythemia vera and the myeloproliferative disorders. 1995;259-291 WB Saunders Company, Philadelphia.
5. Tefferi A., Silverstein M. N., Noel P. Agnogenic myeloid metaplasia. Semin Oncol. 22:1995;327-333.
6. Silverstein M. N. The evolution into and the treatment of late stage polycythemia vera. Semin Hematol. 13:1976;79-84.
7. Kantarjian H. M., O'Brien S., Anderlini P., Talpaz M. Treatment of myelogenous leukemia: current status and investigational options. Blood. 87:1996;3069-3081.
8. Visani G., Finelli C., Castelli U. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 75:1990;4-9.
9. Hoffman R., Silverstein M. N. Agnogenic myeloid metaplasia. Hoffman R., Benz E. J. Jr, Shattil S. J., Furie B., Cohen H. J. Hematology: basic principles and practice. Second edition. 1995;1160-1174 Churchill Livingstone, New York.
10. Wolf B. C., Neiman R. S. Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood. 65:1985;803-809.
11. Silverstein M. N., Brown A. L. Jr, Linman J. W. Idiopathic myeloid metaplasia. Its evolution into acute leukemia. Arch Intern Med. 132:1973;709-712.
12. Wanless I. R., Peterson P., Das A., Boitnott J. K., Moore G. W., Bernier V. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology. 12:1990;1166-1174.
13. Dupriez B., Morel P., Demory J. L. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 88:1996;1013-1018.
14. Anderson J. E., Sale G., Appelbaum F. R., Chauncey T. R., Storb R. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol. 98:1997;1010-1016.
15. Guardiola P., Esperou H., Cazals-Hatem D. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol. 98:1997;1004-1009.
16. Gardner F. H., Nathan D. G. Androgens and erythropoiesis. 3. Further evaluation of testosterone treatment of myelofibrosis. N Engl J Med. 274:1966;420-426.
17. Besa E. C., Nowell P. C., Geller N. L., Gardner F. H. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer. 49:1982;308-313.
18. Chabannon C., Pegourie B., Sotto J. J., Hollard D. Clinical and hematological improvement in a patient receiving danazol therapy for myelofibrosis with myeloid metaplasia. Nouv Rev Fr Hematol. 32:1990;165-166.
19. Lofvenberg E., Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol. 41:1988;375-381.
20. Manoharan A. Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol. 77:1991;252-254.
21. Silverstein M. N., ReMine W. H. Splenectomy in myeloid metaplasia. Blood. 53:1979;515-518.
22. Barosi G., Ambrosetti A., Buratti A. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia. 7:1993;200-206.
23. Mesa R. A., Tefferi A., Jacobsen S. J., Wollan P. C., Silverstein M. N. The incidence and epidemiology of essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study (abstract). Blood. 90 Suppl 1:1997;347a.
24. Greenberger J. S., Chaffey J. T., Rosenthal D. S., Moloney W. C. Irradiation for control of hypersplenism and painful splenomegaly in myeloid metaplasia. Int J Radiat Oncol Biol Phys. 2:1977;1083-1090.
25. Parmentier C., Charbord P., Tibi M., Tubiana M. Splenic irradiation in myelofibrosis. Clinical findings and ferrokinetics. Int J Radiat Oncol Biol Phys. 2:1977;1075-1081.
26. Wagner H. Jr, McKeough P. G., Desforges J., Madoc-Jones H. Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Results of daily and intermittent fractionation with and without concomitant hydroxyurea. Cancer. 58:1986;1204-1207.
27. Slanina J., Vondraczek A., Wannenmacher M. Symptomatic irradiation therapy of the spleen in advanced osteomyelosclerosis [German]. Dtsch Med Wochenschr. 111:1986;1144-1150.
28. Elliott M. A., Chen M. G., Silverstein M. N., Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 103:1998;505-511.
29. Benbassat J., Gilon D., Penchas S. The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. Am J Hematol. 33:1990;128-135.
30. Malmaeus J., Akre T., Adami H. O., Hagberg H. Early postoperative course following elective splenectomy in haematological diseases: a high complication rate in patients with myeloproliferative disorders. Br J Surg. 73:1986;720-723.
31. Barosi G., Ambrosetti A., Centra A. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood. 91:1998;3630-3636.
32. Senn N. Case of splenomedullary leukaemia successfully treated by the use of Röntgen ray. Med Rec. 64:1903;281.
33. Medical Research Council's Working Party for Therapeutic Trials in ¥¥¥Leukaemia. Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy. Br Med J. 1:1968;201-208.
34. Hickling R. A. Treatment of patients with myelosclerosis. Br Med J. 2:1953;411-414.
35. Koeffler H. P., Cline M. J., Golde D. W. Splenic irradiation in myelofibrosis: effect on circulating myeloid progenitor cells. Br J Haematol. 43:1979;69-77.
36. Hernandez J. M., San Miguel J. F., Gonzalez M. Development of acute leukaemia after idiopathic myelofibrosis. J Clin Pathol. 45:1992;427-430.